The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis

详细信息    查看全文

• 作者：Tongna Zhu ; Chuanlong Zhang ; Li Yu ; Jingxian Chen ; Huan Qiu…
• 关键词：respiratory syncytial virus (RSV) ; vaccine prophylaxis ; meta ; analysis
• 刊名：Virologica Sinica
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：30
• 期：5
• 页码：371-378
• 全文大小：759 KB
• 参考文献：Belshe RB, Anderson EL, Walsh EE. 1993. Immunogenicity of purified F glycoprotein of Respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis, 168: 1024-029.CrossRef PubMed
  Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. 2012. Phase 1 study of the safety and immunogenicit of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J, 31: 109-14.CrossRef PubMed
  Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. 2010. New insights for development of a safe and protective RSV vaccine. Hum Vaccin, 6: 482-92.PubMedCentral CrossRef PubMed
  Bradley JS, Connor JD, Compogiannis LS, Eiger LL. 1990. Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections. Antimicrob Agents Chemother, 34: 668-70.PubMedCentral CrossRef PubMed
  Collins PL, Crowe JE. 2007. Respiratory Syncytial Virus and Metapneumo virus. 5th Edition edn Lippincott Williams&Wilkins, Philadelphia, PA, USA.
  Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol, 82: 2040-055.PubMedCentral CrossRef PubMed
  Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res, 162: 80-9.PubMedCentral CrossRef PubMed
  Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia—RSV recombinants or RSV. Vaccine, 10: 475-84.CrossRef PubMed
  Empey KM, Peebles RS, Kolls JK. 2010. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis, 50: 1258-267.PubMedCentral CrossRef PubMed
  Falsey AR, Walsh EE. 1996. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine, 14: 1214-218.CrossRef PubMed
  Falsey AR, Walsh EE. 1997. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine, 15: 1130-132.CrossRef PubMed
  Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Sim?es EA, Wright PF, Sales VM. 2008. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis, 198: 1317-326.CrossRef PubMed
  Falsey AR. 2010. RSV in adults: What do we know? What do we need to know? Where are we going? Paper presented at Proceedings of the 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 2 December.
  Glezen WP, Taber LH, Frank AL, Kasel JA. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child, 140: 543-46.PubMed
  Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, Piedra PA. 2013. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion proteinnanoparticle vaccine. Vaccine, 7: 524-32.CrossRef
  Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, Flyer D, Jani D, Hickman SP, Piedra PA. 2015. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus RecombinantFusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. J Infect Dis, pii: jiv406.
  Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis, 177: 467-69.CrossRef PubMed
  Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med, 360: 588-98.CrossRef PubMed
  Harcourt JL, Karron RA, Tripp RA. 2004. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis, 190: 1936-940.CrossRef PubMed
  Julian PT, Sally Green. 2000. Cochrane Reviewers Handbook 4.1.1 [updated December 2000]. Oxford.
  Kaaijk P, Luytjes W, Rots NY. 2013. Vaccination against RSV: Is maternal vaccination a good alternative to other approaches? Human vaccines & immunotherapeutics 9.
  Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E. 2009. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate
• 作者单位：Tongna Zhu (1)
  Chuanlong Zhang (3)
  Li Yu (1)
  Jingxian Chen (1) (4)
  Huan Qiu (1)
  Weiwei Lyu (1)
  Shenghai Huang (1) (2)
  
  1. Department of Microbiology, School of Basic Medicine, Anhui Medical University, Hefei, 230032, China
  3. Department of Pediatrics, the People’s Hospital of Lu’an City, Lu’an, 237005, China
  4. Department of Pathology and Cell Biology, Columbia University, New York, 10032, USA
  2. School of Life Science, Anhui Medical University, Hefei, 230032, China
  
• 刊物主题：Virology; Medical Microbiology; Oncology; Biochemistry, general; Microbiology; Microbial Genetics and Genomics;
• 出版者：Springer Berlin Heidelberg
• ISSN：1995-820X

文摘

Respiratory syncytial virus (RSV) is the key underlying cause of acute lower respiratory tract infection in infants; however, no licensed vaccine against RSV infection is currently available. This study was undertaken to assess the preventive effect of vaccine on RSV infection. In this metaanalysis, 1,792 published randomized clinical trials of RSV vaccines from Jan 1973 to Sep 2015 were examined. Among thirteen studies that met the inclusion criteria, eleven studies estimated the impact of RSV vaccines and four studies estimated the effect of adjuvants. The odds ratios (ORs) were 0.31 (95% CI, 0.15-.67) and 0.62 (95% CI, 0.29-.34), respectively. We found that RSV subunit vaccines can significantly reduce the incidence of RSV infection and that whether vaccination with adjuvant therapy was an effective strategy still remained to be studied. This analysis of the preventive effect of vaccines on RSV infection has direct applications for the prevention of RSV infections.